Nanoparticle therapy offers new hope for prostate cancer patients
4 hours ago · Researchers developed an approach to treating prostate cancer, successfully eliminating cancerous cells in 73% of patients in the study. Prostate cancer is the second leading cause of cancer death ...
Immune sensitivity links race and survival after prostate cancer ...
4 hours ago · FULL STORY. Black men with advanced prostate cancer have a greater chance of survival after immunotherapy treatment, at least in part, because of ancestral gene variants in immune responses. That ...
A healthy diet may help keep low grade prostate cancer from …
21 hours ago · A new study, led by Johns Hopkins Medicine, shows—for what is believed to be the first time—that a healthy diet may help prevent low grade prostate cancer from progressing to a more aggressive ...
Study Suggests a Healthy Diet May Help Keep Low Grade Prostate Cancer …
23 hours ago · “Many men diagnosed with low grade prostate cancer are interested in changes they can make to reduce the risk of their tumor becoming more aggressive, and the role of diet and nutrition is one of the most commonly asked questions,” says study co-senior author Bruce Trock, Ph.D., a professor of urology, epidemiology and oncology at the Johns ...
New Insights Show ASCL1’s Role in Neuroendocrine Prostate Cancer…
1 day ago · This capacity, known as lineage plasticity, allows prostate cancer cells to transform from adenocarcinoma into neuroendocrine prostate cancer, a much more aggressive and deadly form of the disease. The cellular shapeshifting causes neuroendocrine prostate cancer to develop in 15% of patients receiving androgen receptor therapy.
Xtandi Approved for High-Risk Prostate Cancer - NCI
Jan 5, 2024 · Enzalutamide (Xtandi) can now be used alone or combined with leuprolide to treat some people with prostate cancer who have had a biochemical recurrence.
FDA approves new treatment for advanced prostate cancer
Jul 12, 2023 · In June, the FDA approved a new treatment for the most advanced type of prostate cancer. Patients who have this condition, which is called metastatic castration-resistant prostate cancer (mCRPC), have few therapeutic options, so the approval helps to fill an urgent need.
FDA Approves Promising Therapy for Advanced Prostate Cancer: …
Mar 23, 2022 · Prostate cancer treatment took a major step forward today as the U.S. Food and Drug Administration approved a new therapy that zeros in on cancer cells to destroy them. The treatment, called 177 Lu-PSMA-617, uses a molecule that selectively seeks out and attaches to a specific protein on the cancer cell surface called PSMA (prostate-specific ...
A Promising New Therapy for Advanced Prostate Cancer
Jun 3, 2021 · Prostate cancer treatment stands on the brink of a major advance with the development of a new treatment that zeros in on cancer cells to destroy them. The therapy, called 177 Lu-PSMA-617, uses a molecule that selectively seeks out and attaches to a specific protein on the cancer cell surface.
FDA Approves Relugolix for Advanced Prostate Cancer
Jan 26, 2021 · A new drug approved by the Food and Drug Administration (FDA) is expected to immediately affect the treatment of some men with prostate cancer. In a large clinical trial, the drug, relugolix (Orgovyx), was shown to be more effective at reducing testosterone levels in men with advanced prostate cancer than another commonly used treatment ...
- Some results have been removed